Body Part, Organ, or Organ Component – Page 5

VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private

9 months ago talkbio0Tagged Bio, biotech, Capital, Column (anatomic), Funding, NGM, Series, venture

NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding

iOnctura Secures €80 Million in Series B Financing to Advance Rare Eye Cancer Treatment

10 months ago talkbio0Tagged Cancer Therapeutic Procedure, Infrequent, iOnctura, Malignant tumor of eye, melanoma, roginolisib, Series B financing, Uvea

iOnctura, Series B financing, rare eye cancer, uveal melanoma, roginolisib, cancer treatment

Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery

11 months ago talkbio0Tagged Bio, Diabetes, Digestion, drug absorption, gastric bypass surgery, Intestines, Metabolic Control, Obesity, Oral Therapy, SYNT-101, Syntis, weight-loss surgery

Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.

Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence

11 months ago talkbio0Tagged amber, closed-loop implant, Neurostimulation/modulation, Pelvis, regulatory approval, Structure of pudendal nerve, U.S., United States, Urinary Incontinence

Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.

Biomea’s Early-Stage Diabetes Drug Placed on Full Clinical Hold, Stock Plummets

11 months ago talkbio0Tagged Biomea, crash, Diabetes, Liver, Menin Inhibitor BMF-219, Study on Hold, Toxicity aspects, United States Food and Drug Administration

Biomea, diabetes, clinical hold, FDA, BMF-219, liver toxicity, stock crash

Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy

11 months ago talkbio0Tagged Adenocarcinoma of lung (disorder), Antigens, Biosciences, Cancer Therapeutic Procedure, Cartography, Cervical Atlas, Drug Development, Gilead Sciences, Neoplasms, summit, targets, Technology Platform, Triple Negative Breast Neoplasms

Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.

Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease

11 months ago11 months ago talkbio0Tagged Cardiovascular system, Cessation of life, Chronic Kidney Diseases, Diabetes, Failure (biologic function), Kidney, Mortality Vital Statistics, Nordisk, Obesity, semaglutide, Wegovy

** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment

Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns

11 months ago talkbio0Tagged ARNT gene, aspects of adverse effects, Cancer Research, Clinical Trials, Drug Development, Liver, solid tumor treatment, Toxicity aspects

Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.